Search results for "Respiratory medicine"

showing 10 items of 1534 documents

Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis

1998

Asthma and chronic bronchitis are inflammatory diseases with extracellular matrix (ECM) remodeling and collagen deposition. Collagen homeostasis is controlled by metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). We evaluated MMP and TIMP balance in induced sputum of 10 control, 31 untreated asthmatic, and 16 chronic bronchitic subjects. We first performed zymographic analysis to identify the profile of MMPs. Zymography revealed a similar MMPs profile in all populations studied and that MMP-9 was the major enzyme released. We then measured, using enzyme immunoassay, the concentrations of MMP-9 and of its inhibitor TIMP-1 and evaluated whether airflow limitation m…

AdultPulmonary and Respiratory MedicineChronic bronchitisAdolescentNeutrophilsCell CountEnzyme-Linked Immunosorbent AssayMatrix metalloproteinaseCritical Care and Intensive Care MedicinePathogenesisLeukocyte CountSurface-Active AgentsForced Expiratory VolumemedicineHomeostasisHumansProtease InhibitorsCollagenasesBronchitisAgedAsthmaTissue Inhibitor of Metalloproteinase-1business.industryMacrophagesRespiratory diseaseSputumSodium Dodecyl SulfateMiddle AgedTissue inhibitor of metalloproteinasemedicine.diseaseAsthmaExtracellular Matrixrespiratory tract diseasesAirway ObstructionMatrix Metalloproteinase 9Chronic DiseaseImmunologyBronchitisSputumElectrophoresis Polyacrylamide GelCollagenmedicine.symptomPulmonary Ventilationbusiness
researchProduct

Increased Levels of Elastase and α1-Antitrypsin in Sputum of Asthmatic Patients

1998

Asthma and chronic bronchitis are inflammatory diseases associated with remodeling of the extracellular matrix (ECM). Elastin, a major component of the ECM in the airways, has been previously found to be disrupted in asthma and chronic bronchitis. This study was aimed at evaluating whether elastin disruption might be associated with an imbalance between elastase (active and total) and alpha1-proteinase inhibitor (alpha1-PI), the main inhibitor of elastase. We measured elastase and alpha1-PI in induced sputum obtained from 16 control subjects, 10 healthy smokers, 19 asthmatic patients, and 10 chronic bronchitis patients. We also assessed the possible origin of elastase, evaluating its levels…

AdultPulmonary and Respiratory MedicineChronic bronchitisCell CountCritical Care and Intensive Care MedicinePathogenesisReference ValuesForced Expiratory VolumemedicineHumansBronchitisSalivaSerum AlbuminAgedAsthmaPancreatic Elastasebiologybusiness.industrySmokingElastaseRespiratory diseaseSputumMiddle Agedmedicine.diseaseAsthmarespiratory tract diseasesalpha 1-AntitrypsinChronic DiseaseImmunologybiology.proteinSputumBronchitismedicine.symptombusinessElastinAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Volatile organic compounds fingerprint of Alzheimer’s disease.

2015

Alzheimer's disease (AD) is a profoundly life changing condition and once diagnosis occurs, this is typically at a relatively late stage into the disease process. Therefore, a shift to earlier diagnosis, which means several decades before the onset of the typical manifestation of the disease, will be an important step forward for the patient. A promising diagnostic and screening tool to answer this purpose is represented by breath and exhaled volatile organic compounds (VOCs) analysis. In fact, human exhaled breath contains several thousand of VOCs that vary in abundance and number in correlation with the physiological status. The exhaled VOCs reflect the metabolism, including the neuronal …

AdultPulmonary and Respiratory MedicinePathologymedicine.medical_specialtyTime FactorsPhysiologyDiseaseVolatile organic compounds (VOCs)Neurodegenerative diseaseAlzheimer's disease; Breath analysis; Neurodegenerative disease; VOC fingerprint; VOC real time analysis; Volatile organic compounds (VOCs); Adult; Aged; Aged 80 and over; Alzheimer Disease; Biomarkers; Breath Tests; Humans; Middle Aged; Respiratory Rate; Time Factors; Volatile Organic Compounds; Young Adult; Neuroscience (all); Physiology; Pulmonary and Respiratory MedicineYoung AdultRespiratory RateAlzheimer DiseaseVOC fingerprintmedicine80 and overHumansDisease processScreening toolAgedAged 80 and overVolatile Organic CompoundsNeuroscience (all)ChemistryGeneral NeuroscienceLate stageBreath analysisAlzheimer's diseaseMiddle AgedAlzheimer's disease; Breath analysis; Neurodegenerative disease; VOC fingerprint; VOC real time analysis; Volatile organic compounds (VOCs)Breath gas analysisBreath TestsImmunologyVOC real time analysisBiomarkers
researchProduct

GINA 2019: a fundamental change in asthma management

2019

GINA no longer recommends treating adults/adolescents with asthma with short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations.http://bit.ly/310LLzE

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAdolescentMild asthmaGlobal HealthAsthma managementAdministration InhalationHumansMedicineAnti-Asthmatic AgentsDisease management (health)Monitoring PhysiologicRandomized Controlled Trials as TopicAsthmaInhalationbusiness.industryInhalerDisease Managementmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesBudesonide/formoterolPractice Guidelines as TopicFundamental changebusinessmedicine.drugEuropean Respiratory Journal
researchProduct

Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Societe de Pneumo…

2016

Revue des Maladies Respiratoires - In Press.Proof corrected by the author Available online since samedi 16 avril 2016

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAdolescent[SDV]Life Sciences [q-bio]MEDLINEYoung Adult03 medical and health sciences0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesPulmonary medicinePulmonary MedicinemedicineHumansAsthmatic patient030212 general & internal medicineYoung adultChildSocieties MedicalComputingMilieux_MISCELLANEOUSMonitoring PhysiologicAsthmaAsthma therapy[ SDV ] Life Sciences [q-bio]business.industryDisease progressionasthmamedicine.disease3. Good healthasthme[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases030228 respiratory systemDisease ProgressionFrancebusiness
researchProduct

SQ HDM SLIT-tablet (ALK) in treatment of asthma – Post hoc results from a randomised trial

2014

SummaryIntroductionIn a double-blind, placebo-controlled trial (EudraCT identifier: 2006-001795-20), the standardised quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) was investigated.MethodThe trial included 604 subjects, ≥14 years, with mild-moderate HDM allergic asthma. Subjects were randomised 1:1:1:1 to 1, 3 or 6 SQ-HDM or placebo once daily. The primary endpoint was reduction in inhaled corticosteroid (ICS) after one year. ICS reduction, asthma quality of life questionnaire (AQLQ) and asthma control questionnaire (ACQ) score was analysed post hoc in a subgroup with daily ICS use of 400–800 μg and ACQ score of 1–1.5, corresponding to partly contr…

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classPopulationPlaceboHouse dust miteDouble-Blind MethodQuality of lifeSurveys and QuestionnairesmedicineClinical endpointAnimalsHumansSLIT-tabletBudesonideeducationGlucocorticoidsICS reductionAsthmaHouse dust miteSublingual Immunotherapyeducation.field_of_studybiologybusiness.industryPyroglyphidaemedicine.diseasebiology.organism_classificationAsthma; Asthma quality of life; House dust mite; ICS reduction; SLIT-tabletAsthmaTreatment OutcomeAsthma Control QuestionnaireQuality of LifeCorticosteroidAsthma quality of lifebusinessTabletsRespiratory Medicine
researchProduct

Omalizumab (Xolair®) improves quality of life in adult patients with allergic asthma: a review

2003

Abstract Physicians are increasingly aware that asthma causes significant impairment of the patient's physical, psychological, and social well-being. Whilst standard clinical endpoints provide significant information on airway status during treatment, it is important to determine whether such improvements overcome the functional impairment that patients have to deal with on a daily basis. As such, assessment of health-related quality of life (QoL) is an important aspect of asthma management in clinical practice. Omalizumab (Xolair ® ) is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody that represents a new therapeutic approach to IgE-mediated diseases such as allergi…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentOmalizumabAntibodies Monoclonal HumanizedImmunoglobulin EPlaceboTherapeutic approachDouble-Blind MethodQuality of lifeInternal medicinemedicineClinical endpointHumansAnti-Asthmatic Agentsanti-IgEChildquality of life.AgedAsthmabiologybusiness.industryRespiratory diseaseAntibodies MonoclonalMiddle Agedmedicine.diseaseAsthmaAntibodies Anti-IdiotypicQuality of Lifebiology.proteinPhysical therapyomalizumabbusinessAttitude to Healthallergic asthmamedicine.drugRespiratory Medicine
researchProduct

Myocardial and Peripheral Lymphocytic Transcriptomic Dissociation of β-adrenoceptors and G Protein–coupled Receptor Kinases in Heart Transplantation

2009

Background The genetic expression of adrenergic receptors plays an important pathophysiologic role in heart failure. G protein–coupled receptor kinases (GRKs) desensitize the β-receptor to catecholaminergic stimulation. It has been suggested that their mRNA expression in peripheral lymphocytes could mirror the changes in their myocardial expression in the failing heart, but this relationship between the myocyte and lymphocyte has not been studied in heart transplantation (HT). The objective of this study was to analyze adrenergic receptor and GRK mRNA expression in myocardium and lymphocytes and their correlation. Methods Twenty-three HT patients without evidence of acute rejection or echoc…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdrenergic receptorBiopsymedicine.medical_treatmentLymphocyteInternal medicineReceptors Adrenergic betamedicineHumansLymphocytesRNA MessengerReceptorHeart transplantationTransplantationG protein-coupled receptor kinasebiologybusiness.industryGene Expression ProfilingMyocardiumBeta adrenergic receptor kinaseHeartMiddle AgedG-Protein-Coupled Receptor Kinasesmedicine.diseaseTransplantationEndocrinologymedicine.anatomical_structureHeart failurebiology.proteinHeart TransplantationSurgeryReceptors Adrenergic beta-2Receptors Adrenergic beta-1Cardiology and Cardiovascular MedicinebusinessThe Journal of Heart and Lung Transplantation
researchProduct

Tiotropium add-on therapy reduces seasonal peaks of asthma worsening in adults with symptomatic severe asthma

2019

Despite the use of preferred controller therapies (including inhaled corticosteroids [ICS] with or without additional long-acting β2-agonists [LABAs]), a large proportion of patients with asthma have poor disease control, leaving them at risk of recurring symptoms and episodes of asthma exacerbations and worsening [1, 2]. Such problems can be triggered by many different environmental factors including pollutants, respiratory infections or allergens [3]. They may occur sporadically, but are often determined by seasons, mirroring seasonal patterns of allergen exposure and prevalence of respiratory viral infection [3, 4]. They can cause reduced quality of life, increase asthma burden [2, 3], a…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthma03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Administration InhalationmedicineHumans030212 general & internal medicineTiotropium BromideAsthmaWork productivitybusiness.industryConflict of interestmedicine.diseaseAsthmaBronchodilator AgentsAdd on therapy030228 respiratory systemFamily medicineAbsenteeismDrug Therapy CombinationSeasonsALLERGEN EXPOSUREbusinessEuropean Respiratory Journal
researchProduct

Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the lit…

2018

This review provides an overview of the role of long-term treatment of severe asthma with oral corticosteroids (OCS) and its associated side-effects in adults. It is based on a systematic literature search conducted in MEDLINE, Embase and the Cochrane Library to identify relevant studies. After a short overview of severe asthma and its treatment we present studies showing a dose–response relationship in asthmatic patients treated with OCS and then consider by organ systems the undesired effects demonstrated in clinical and epidemiological studies in patients with OCS-dependent asthma. It was found that the risk of developing various OCS-related complications, including infections, diabetes …

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtySevere asthmaOsteoporosisMEDLINEAdministration OralCochrane Library03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesDiabetes mellitusHealth careEpidemiologymedicineHumans030212 general & internal medicineIntensive care medicineRandomized Controlled Trials as TopicAsthmaDose-Response Relationship Drugbusiness.industrymedicine.diseaseAsthma030228 respiratory systembusinessEuropean Respiratory Journal
researchProduct